| Vol. 9.03 – 26 January, 2021 |
| |
|
|
| Scientists evaluated the clinical outcome and circulating immune responses of eight patients with surgically resected stage IIIB/C or IVM1a/b melanoma, [Nature Medicine] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors demonstrated that tumor-infiltrating γδ T cells isolated from patients with ovarian cancer have distinct T cell receptors and exhibit more innate-like functions compared to blood- or ascites-derived γδ T cells. [Science Translational Medicine] |
|
|
|
| Scientists attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous dendritic cell vaccine and conducted a single-arm, two medical centers, pilot study initiated by the investigator. [Signal Transduction and Targeted Therapy] |
|
|
|
| An innovative rolled‐up impedimetric microfulidic sensor, called sensor‐in‐a‐tube, was introduced for the simultaneous analysis of single human monocytes CD14+ and their extracellular medium upon liposaccharides‐mediated activation. [Small] |
|
|
|
| Scientists evaluated CD1d expression in a cohort of 78 untreated chronic lymphocytic leukemia patients and generated a CD1d-specific Vγ9Vδ2-T cell engager based on single-domain antibodies. [Clinical Cancer Research] |
|
|
|
| Investigators developed nanoparticle-based bispecific T-cell engagers, which were liposomes decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs targeting the cancer antigen. [Leukemia] |
|
|
|
| Researchers found that the related transcription factor TAL1 was dispensable in several human T-cell acute lymphoblastic leukemia (T-ALL) cell lines that contained SIL-TAL1 chromosomal deletions driving its overexpression, indicating that evolution to oncogene independence could also occur in human T-ALL. [Leukemia] |
|
|
|
| Scientists showed that multiple synthetically accessible bryologs replicated the anti-inflammatory effects of bryostatin-1 on innate immune cells in vitro, and a lead bryolog attenuates neuroinflammation in vivo. [Cell Chemical Biology] |
|
|
|
| The authors investigated if the modulation of the cytokine environment in lung cancer with IL‐2 or IL‐15 rendered NK cells resistant to suppression by PGE2. [EMBO Reports] |
|
|
|
| Researchers observed that in vitro–expanded primary human T cells exhibited perfect adaptation with respect to cytokine production to constant antigen stimulation across a 100,000-fold variation in affinity with partial T cell receptors down-regulation. [Science Signaling] |
|
|
|
| Scientists studied GRP94 in M1/LPS + IFNγ and M2/IL-4 primary macrophages derived from human monocytes, in basal and endoplasmic reticulum (ER) stress conditions induced by thapsigargin, an inducer of ER calcium depletion and tunicamycin, an inhibitor of N-glycosylation. [Cell Death & Disease] |
| |
|
|
|
| The authors review the current clinical advances and experimental findings supporting the utility of an anti-inflammatory approach to the treatment of solid malignancies. [Nature Reviews Clinical Oncology] |
|
|
|
| Investigators discuss the essential roles of microglia and innate immune signaling in the assembly and maintenance of a properly functioning nervous system. [Nature Reviews Immunology] |
|
|
|
| Scientists describe selected examples of natural and synthetic carbohydrate-based adjuvants and their application in synthetic self-adjuvanting vaccines, while also discussing current understanding of their molecular mechanisms of action. [Nature Reviews Chemistry] |
|
|
|
|
| Precision BioSciences, Inc. announced that the FDA has accepted the Investigational New Drug application for PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory Non-Hodgkin Lymphoma. [Precision BioSciences, Inc. (Globe Newswire, Inc.)] |
|
|
|
| Immunicum AB announced that it has received Orphan Drug Designation from the FDA for the company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue Sarcoma. [Immunicum AB (GlobeNewswire, Inc.)] |
|
|
|
|
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| The University of Utah School of Medicine – Salt Lake City, Utah, United States |
|
|
|
| Systimmune, Inc. – Redmond, Washington, United States |
|
|
|
| University of Florida – Gainesville, Florida, United States |
|
|
|
|